NCT00314119 2026-03-11
Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
National Institutes of Health Clinical Center (CC)
Completed
Clinical Trials
13 trialsNCT00111384 2026-02-17
Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
National Institutes of Health Clinical Center (CC)
Completed
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
NCT02332902 2023-12-20
DCLNF1
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT01347307 2020-06-18
Stereotactic Body Radiotherapy for Spine Tumors
Mercy Research
Phase NA Completed
NCT02096471 2019-01-10
MEK Inhibitor
University of Alabama at Birmingham
Phase 2 Completed
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01140360 2017-07-02
0908-09
Indiana University
Phase 1/2 Completed
NCT01275586 2017-04-12
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Indiana University
Phase EARLY_PHASE1 Completed
NCT00657202 2016-07-07
Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
Massachusetts General Hospital
Phase EARLY_PHASE1 Completed
NCT01031901 2012-02-27
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
The University of Texas Health Science Center, Houston
Phase 1 Completed